Sequence: GRKKRRQRRRG (Tat-G: Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly)
siRNA (fluorescently labeled for tracking); Alexa-dextran (10 kDa) used as model siRNA
| Experiment Id | EXP001774 |
|---|---|
| Paper | Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating pe |
| Peptide | Tat-G (Tat analog) |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 0.5 mg/mL FAM-siRNA for intranasal dosing (80 µL total; reported dose 40 µg) |
| Mixing Ratio | N/P = 20 used for in vivo studies (complexation tested N/P 1–30) |
| Formulation Format | CPP-modified PEG-PCL polymeric nano-micelle / polyion complex |
| Formulation Components | MPEGePCLeTat (PEG-PCL copolymer conjugated to Tat-G) complexed with siRNA (or Alexa-dextran model) |
| Size Nm | 50.00 |
| Zeta Mv | 10.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Sprague–Dawley male rats, 8-week old |
| Administration Route | Intranasal (80 µL total over 30 min; 5–10 µL drops every 2–3 min); comparator: IV tail vein (100 µL) |
| Output Type | Brain/olfactory bulb delivery (fluorescence quantification & imaging) |
| Output Value | Intranasal delivery produced significantly higher brain levels than IV; Tat-micelles increased brain/olfactory bulb and trigeminal nerve/CSF signal vs naked |
| Output Units | |
| Output Notes | Primarily distribution/transport study via olfactory and trigeminal pathways (FAM-siRNA & Alexa-dextran tracer). No in vivo gene knockdown/phenotype shown. |
| Toxicity Notes | No apparent toxicity discussed in this paper for the intranasal siRNA study |
| Curation Notes |